coming back to life ?

Plant Health Care PLC
21 February 2008


Embargoed for release: 07.00, 21 February 2008

Plant Health Care ('PHC')

Statement regarding a Monsanto announcement

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, would like to draw investors' attention to an announcement
issued by Monsanto on 20 February 2008. The announcement refers to PHC in two
paragraphs (see below) and PHC confirms that the Monsanto release is entirely in
line with the PHC release dated 12 December.

The Monsanto announcement is set out in full below.

'NEW YORK, Feb. 20 Monsanto (NYSE: MON) Company's technologies have placed it in
a unique position to help farmers meet the changing supply-demand patterns of
global agriculture, Monsanto's Executive Vice President of Strategy and
Operations, Carl Casale, will tell investors tomorrow. Casale will deliver his
remarks as part of a presentation at the Morgan Stanley Basic Materials
Conference 2008 on Thursday in New York.

Casale's presentation will discuss how there has been a fundamental shift in the
agricultural landscape creating a new demand-driven agriculture market fueled by
three main factors. These factors include increased protein demand from rising
incomes, demand for grain from China and biofuels.

'The real demand pull comes from China,' Casale said. 'To meet the protein
demands of this growing population, China will look outside of its agricultural
sector, providing an enormous demand pull for grain over the next decade.'

'The solution to meeting these demands is yield,' Casale said. 'In a
demand-driven environment opportunity is defined by scarcity or innovation,' he
said. 'Monsanto's strategy is targeted on innovation -- discovering and
developing technology that is game changing.'

Casale believes the company's innovation focus sets it apart, both in the value
created for farmers and the company's strategic opportunity. 'We will grow
because of what we do, how we invest and what we deliver -- not because of what
the commodity cycles do,' he said.

Casale believes that the company's ability to provide technology to boost
per-acre productivity will be key to helping farmers meet the needs of a
demand-driven market. These potential technologies, like Roundup Ready 2 Yield
soybeans, SmartStax corn and nitrogen-utilization corn are being developed to
drive yields to meet these demands, he said.

Monsanto Establishes Global Seed Treatment Platform

As a technology company with strong cash generation, Monsanto has the
opportunity to invest in growth areas for agriculture, Casale said.

As part of his presentation, Casale will announce that Monsanto is establishing
a global seed treatment platform. The company has entered into separate
agreements with Becker Underwood and Plant Health Care Inc., as novel components
of the platform for delivering proprietary seed treatments for corn, soybeans
and cotton.

The global platform is a natural complement to the company's seed strategy and
yield-enhancing technology pioneered by Monsanto through biotechnology and
breeding, as well as its collaborative approach to new technologies, Casale
said.

'As we develop our seed-treatment platform, we're planning to stake a leading
position in an underserved, but emerging category and to enter into a variety of
licensing and supply agreements,' Casale said. 'Seed treatments are the next
step in yield protection and delivery, and represent a high-margin global
opportunity.'

The global seed treatment industry generates annual sales of greater than $1.5
billion, with almost $900 million in the crops key to Monsanto's business.
Currently, Monsanto treats more than 1 billion pounds of seed each year and sees
the potential to expand treatment to new crops and new geographies, Casale said.

'The realizable yield in seeds is so valuable to farmers that seed treatments
are the next logical complement to further protect yield created by advanced
breeding and biotech traits,' said Casale.

Monsanto plans to begin offering seed treatments as early as the 2009 season. In
2009, Monsanto plans to treat all Roundup Ready 2 Yield soybeans with a
proprietary treatment, aimed at incremental yield boost in soybeans. Similarly
in 2010, Monsanto plans to have a proprietary seed treatment for the launch of
its SmartStax corn product, and the company is also working to have a seed
treatment solution for its Deltapine cotton varieties by 2011.

The agreement between Monsanto and Becker Underwood is focused on evaluating a
biological seed treatment aimed at helping soybeans improve both their nitrogen
fixation ability and overall plant performance. Monsanto is also working with
Plant Health Care Inc. to develop and commercialize a novel seed-based solution
for nematodes, a plant parasite that can severely limit crop yields around the
world in crops such as corn, soybeans, cotton and vegetables.

Casale's presentation slides and simultaneous audio webcast of the presentation
may be accessed by visiting the company's web site at
http://www.monsanto.com/

investors . Following tomorrow's live broadcast set for 8 a.m. ET, a replay of
the webcast will be available for two weeks through this same link.

Monsanto Company is a leading global provider of technology-based solutions and
agricultural products that improve farm productivity and food quality.' For
information on Monsanto, see:
http://www.monsanto.com/
.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are 'forward-looking statements,'
such as statements concerning the company's anticipated financial results,
current and future product performance, regulatory approvals, business and
financial plans and other non-historical facts. These statements are based on
current expectations and currently available information. However, since these
statements are based on factors that involve risks and uncertainties, the
company's actual performance and results may differ materially from those
described or implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, among others: continued
competition in seeds, traits and agricultural chemicals; the company's exposure
to various contingencies, including those related to intellectual property
protection, regulatory compliance and the speed with which approvals are
received, and public acceptance of biotechnology products; the success of the
company's research and development activities; the outcomes of major lawsuits,
including proceedings related to Solutia Inc.; developments related to foreign
currencies and economies; successful operation of recent acquisitions;
fluctuations in commodity prices; compliance with regulations affecting our
manufacturing; the accuracy of the company's estimates related to distribution
inventory levels; the company's ability to fund its short-term financing needs
and to obtain payment for the products that it sells; the effect of weather
conditions, natural disasters and accidents on the agriculture business or the
company's facilities; and other risks and factors detailed in the company's most
recent periodic report to the SEC. Undue reliance should not be placed on these
forward-looking statements, which are current only as of the date of this
release. The company disclaims any current intention or obligation to update any
forward-looking statements or any of the factors that may affect actual results.

CONTACT: media, Lee Quarles, +1-314-694-2330, or investors, Scarlett Lee
Foster, +1-314-694-8148, both of Monsanto

Web site:
http://www.monsanto.com/


For further information please visit
www.planthealthcare.com
or contact:

Plant Heath Care plc Evolution Securities Tavistock
Limited Communications
John Brady, Chief Executive Tim Worlledge/Tim Jeremy Carey/Matt
Redfern Ridsdale
Tel: 001 603 525 3702 Tel: 020 7071 4300 Tel: 020 7920 3150

Plant Health Care PLC
31 March 2008


For immediate release 31 March 2008


PLANT HEATH CARE PLC

('Plant Heath Care' or 'the Company')

Results for the year ended 31 December 2007


Plant Heath Care, (AIM: PHC.L), a leading provider of natural products for
plants and soil, announces its results for the year ended 31 December 2007.


Financial highlights:


Turnover up 34% to $18.3 million (2006: $13.7 million)

Gross profit up 37% to $8.4 million (2006: $6.1 million)

Gross margin up from 44.7% to 45.6%
- due to upfront fee income from our partners and entry into the
higher margin Harpin business

Loss before exceptional costs, costs of share-based payments, interest
and taxation of $4.4 million (2006: loss $2.5 million)

Net loss of $5.4 million (2006: loss of $3.0 million)

Net cash at 31 December of $9.8 million (2006: $3.7 million)


Operational highlights:

First Myconate manufacture and supply agreement signed with Bayer
Cropscience in January 2007
- exclusive for seed-coated corn, soybean, cotton and sunflower

Agreement signed with Monsanto to evaluate, develop and commercialise
certain applications of the Harpin-based technology
- made possible by the acquisition of the Harpin intellectual
property from Eden Bioscience

Significant contribution from US agriculture division in its first full
year of operation

New share capital of $10 million raised in September

Post year end: Steve Weaver appointed to the Board of Directors as
Finance Director on 28 March 2008



Commenting on the results, Chief Executive John Brady said: 'Last year was
another important one for Plant Health Care. We signed our first two major
partnership deals with Bayer CropScience and Monsanto for Myconate and Harpin
respectively. These agreements have taken us further towards achieving our goal
of becoming the world's leading supplier of natural products for the promotion
of plant heath and growth.


'Plant Health Care's ability to fulfil the need for higher yields on existing
land has been validated by these partnership deals. With our stable of effective
natural technologies, we are extremely well positioned to offer further
solutions to help meet this global challenge, and as such, the macro environment
remains favourable.


'In 2007 we continued our pursuit of sales growth. Our performance was pleasing
with record revenue in almost all business units; in particular, in its first
full year of operation, our US agriculture division successfully introduced
Plant Health Care into what will be an important market for our future success.'


For further information:
Plant Heath Care plc

John Brady, Chief Executive

31 March - 4 April Tel: 020 7920 3150

Therafter: 001 603 525 3702


Evolution Securities Limited Tavistock Communications

Tim Worlledge/ Tim Redfern Jeremy Carey/Matt Ridsdale

Tel: 020 7071 4300 Tel: 020 7920 3150


Notes to editors

Plant Heath Care was established in 1995 in Pittsburgh (Pennsylvania) in the
United States. Its products are aimed at the agriculture, commercial landscaping
and land reclamation industries, through both direct sales and supply and
distribution agreements with major agrichemical industry partners. Plant Health
Care's products create both environmental and economic benefits for our
customers and capitalise upon long-term trends towards natural systems and
biological products to provide plant health and growth.

A blue star shines brightly in a sea of red (referring to my portfolio) PHC is class ! The chart is self explanatory . It seems to be just me posting here ,but shall keep posting anyway.

Neil, I took my profits last year, could have more but hey I'm happy with the tripling my money on this. Take a look at PIM who are much smaller than PHC but also have environmentally friendly solutions to increasing crop yields and dealing with parasite issues. They are at similar stage to PHC 2 years ago and IMO there is a good chance sp will rise once strategic deals are in place.
I recently bought in at 46.95p and expecting good profit long-term. Expect some announcements over the coming months.

Thanks for that Andy ,I will take a good look at PIM, and good to hear you made an excellent return.
Neil

RNS Number : 8083V
Plant Health Care PLC
03 June 2008






3 June 2008


For immediate release







Plant Health Care plc

('Plant Health Care' or 'the Company')




FIELD TRIALS

Pre-Tect delivers strong results in UK fruit trials







Plant Health Care plc (AIM: PHC.L), a leading provider of natural products for plants and soil, is pleased to report the success of independent UK trials of its Harpin based PreTect product on cherries, published in Horticulture Week, and on other soft fruit including strawberries and raspberries.




The trials undertaken by Farm Advisory Services Team ('FAST') have shown that protein-based Pre-Tect can help cherries from cracking during wet harvests and help to increase the shelf-life of soft fruits.




The results of the trials demonstrated that cherries from an orchard where an alternative material was applied with calcium and which experienced 110mm of rainfall exhibited 55 per cent cracking on the day sampled. Following more rainfall, the orchard was written off. In contrast, cherries from an orchard treated with PreTect and calcium, which were exposed to the same amount of rain, exhibited only 2.5 per cent cracking when sampled at the same time.




'Where no anti-crack treatment measures were taken the crop was a total write-off. Where alternative materials were used, some reduction in cracking was initially seen, but with continuing wet weather most fruits succumbed and growers walked away from the crop. However, where a full programme of PreTect was used, virtually no cracking was seen - even with over 120mm of rain falling during the main picking period' - said Don Vaughan, FAST's cherry agronomist. The trials were undertaken last summer when more than 200mm of rain fell during the cherry harvesting period'.




One of the growers participating in the trial, Henry Bryant of Faversham based Bryant & Partners, used Pre-Tect on his cherries in 2007 and also experienced good results. He said 'Without Pre-Tect I doubt we would have picked even 10 per cent of our cherries last year. As it was, we picked at least 80 per cent of the crop. An added bonus was the extended shelf life Pre-Tect appeared to give the fruit. This was remarked on by several customers when they compared our fruit to others'.




Other trials on strawberry 'Elsanta', 'Everest' and 'Symphony' varieties involved an application of PreTect two weeks before harvest. Results showed that the control fruit exhibited 20% rot whilst test fruit showed only 8% rots. Both were stored at 20oc for 14 days.




The 'Octavia' variety was used for raspberry trials again treated two weeks before harvest. Control fruit showed 40% rots whilst fruit treated with PreTect showed 10% rots following storage at 10oc for 14 days.




An excessively wet picking season in 2007 resulted in traditional botrytis treatments being 'maxed out' early in the season. With the added benefit of no harvest interval, however, Pre-Tect could be used to the day of harvest, extending the fruit's storage capability by 20%. 'When aimed at extending the shelf life of soft fruit, PreTect has proved excitingly effective,' said Rob Cook, soft fruit agronomist with FAST.




Charles Atkins of C.E. Murch at Blean, Canterbury used PreTect on his raspberry crop for the first time in 2007. 'There was a definite increase in fruit firmness at harvest time and I believe this is having a positive effect on the shelf life of my crop. This has been remarked upon by my customers'.




-Ends-




For further information please visit www.planthealthcare.com or contact:

Plant Health Care says in talks with agri cos for Myconate, Harpin products
AFX


LONDON (Thomson Financial) - Plant Health Care PLC. said it is in talks with several agriculture companies regarding the use of its Myconate and Harpin technologies on additional crops.

The company also said it remains on track to announce another important Harpin deal with one of the world's leading agricultural companies in the near term.



TFN.newsdesk@thomson.com

RNS Number : 6942W
Plant Health Care PLC
13 June 2008

TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES




1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):




PLANT HEALTH CARE plc




2. Reason for the notification (please state Yes/No): ( )

An acquisition or disposal of voting rights: (YES)

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( )

An event changing the breakdown of voting rights: ( )

Other (please specify): ()




3. Full name of person(s) subject to the notification obligation (iii):




Generation Investment Management LLP




4. Full name of shareholder(s) (if different from 3.) (iv):




Generation IM Climate Solutions Fund, L.P.




5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v):

10/06/2008

6. Date on which issuer notified:




12/06/2008




7. Threshold(s) that is/are crossed or reached:



5%




8. Notified details:




A: Voting rights attached to shares




Class/type of shares if possible using the ISIN CODE
Situation previous to the Triggering transaction (vi)



Number of shares
Number of voting Rights (viii)

GB00B01JC540
1,640,000
1,640,000





Resulting situation after the triggering transaction (vii)

Class/type of shares if possible using the ISIN CODE
Number of shares

Number of voting rights (ix)

% of voting rights






Direct (x)
Indirect (xi)
Direct
Indirect

GB00B01JC540
2,355,000


2,355,000


5.256%





B: Financial Instruments




Resulting situation after the triggering transaction (xii)




Type of financial instrument




Expiration Date (xiii)






Exercise/Conversion Period/Date (xiv)





Number of voting rights that may be acquired if the instrument is exercised/ converted.



% of voting rights



















Total (A+B)




Number of voting rights



% of voting rights

2,355,000
5.256%





9. Chain of controlled undertakings through which the voting rights and/or the financial instruments
are effectively held, if applicable (xv):




Generation Investment Management LLP - Indirect:

Generation IM Climate Solution Fund, L.P. : 2,355,000 5.256% = Total Position




Proxy Voting:




10. Name of the proxy holder:




N/A




11. Number of voting rights proxy holder will cease to hold:




N/A




12. Date on which proxy holder will cease to hold voting rights:




N/A




13. Additional information:




Notification is based on using the total voting rights figure of 44,802,000.




14. Contact name:




(i) Andrew Wood FCIS, Company Secretary




(II) Tim Redfern, Evolution Securities Limited




(iii) Jeremy Carey, Tavistock Communications




15. Contact telephone number:




+44 (0)20 8866 5702

+44 (0)20 7071 4300

+44 (0)20 7920 3150




Annex to Notification Of Major Interests In Shares (xvi)




A: Identity of the person or legal entity subject to the notification obligation




Full name (including legal form for legal entities):




Generation Investment Management LLP




Contact address (registered office for legal entities):




4 Cork Street
London
W1S 3LG




Phone number:




020 7534 4700




Other useful information (at least legal representative for legal persons):




Peter Harris




B: Identity of the notifier, if applicable (xvii)




Full name:







Contact address:





Phone number:




Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)




END

13 June 2008

4 July 2008










Plant Health Care plc

('Plant Health Care' or 'the Company')




More Potential Benefits Indicated for Plant Health Care's Myconate




VA Mycorrhizal fungi produce glomalin,

a soil constituent that locks up soil carbon




Plant Health Care (AIM: PHC.L), a leading provider of natural products for plants and soil announces that the United States Department of Agriculture, Agricultural Research Service (USDA-ARS) has found that a soil constituent known as glomalin and produced by beneficial vesicular arbuscular mycorrhizal fungi (VAM) locks up soil carbon. VAM development and colonisation of plant roots is known to be stimulated by Plant Health Care's Myconate. The findings on glomalin come from research conducted by Kristine Nichols, a microbiologist at the USDA-ARS in Mandan, North Dakota. The report is based in part on carbon-dating studies of glomalin.




Dr. Greg Lewis, Vice President, Corporate Development at Plant Health Care says: 'VAM fungi act as a secondary plant root system, increasing a crop's ability to access and use available moisture and nutrients. By taking advantage of these known benefits of VA mycorrhizal fungi, growers can now not only improve the performance of their crops and enhance soil fertility, they may also be able to contribute to the long-term reduction of carbon dioxide from the atmosphere. Our Myconate product has been shown to encourage the development of VAM fungi in a growing number of agricultural crops.'




Glomalin is a sticky substance secreted by threadlike fungal structures called hyphae that funnel nutrients and water to plant roots. It is named after the Glomerales, the group of fungi to which some VAM fungi belong. So far, VAM fungi appear to be the only producers of glomalin.




Greg Lewis added, 'Plant Health Care has known for some time the benefits of mycorrhizal fungi, including the Glomerales, to plants and the soil and it is most encouraging to see the ARS document that these same organisms can contribute to carbon storage in soils. The ARS suggests that glomalin can keep carbon from decomposing for up to100 years. This is significant for the reduction of carbon dioxide in the atmosphere.'




Plant Health Care offers the product Myconate, which stimulates the colonization of plants by native VAM fungi already present in the soil. Myconate offers the potential to increase yields and tests are underway to determine if the expanded root mass observed on Myconate-treated crops will allow for a reduction in irrigation and nutritional inputs as well. Preliminary on-farm trials have shown very promising results in row crops, cereals and several vegetable crops such as carrots, potatoes and celery. Other potential crops being studied include perennials like fruits and vines and more vegetable crops like peppers, tomatoes and cucurbits. Myconate can be applied to a seed or watered into the ground very easily via irrigation systems. Myconate's net effect is to stimulate the colonization of native VAM soil fungi on plant roots, improving a crop's ability to access moisture and nutrients.




- Ends -




For Further Information:




John Brady
Evolution Securities Limited
Tavistock Communications

Chief Executive
Tim Worlledge/Grant Schaffer
Jeremy Carey/Simon Compton

Tel: 001 603 525 3702
Tel: 020 7071 4300
Tel: 020 7920 3150








Myconate, ProAct, N-Hibit PHC, and the Plant Health Care, Inc. logo are trademarks of Plant Health Care, Inc.




Notes to editors:

'Glomalin is Key to Locking up Soil Carbon' By Don Comis was published on June 17, 2008 on the USDA-ARS website at www.ars.usda.gov/is/pr/2008/080617.htm?pf=1







About Plant Health Care




Plant Health Care plc is a leading provider of natural products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 70 employees and has operations in the United States, Mexico, the United Kingdom, Spain, and the Netherlands. The Company listed on the AIM market of the London Stock Exchange in July 2004. Ticker symbol is PHC.




PHC's products are aimed at the landscape, agriculture and land reclamation industries and are environmentally beneficial. Through the commercialization of these products, PHC is capitalizing on current long-term trends toward natural systems and biological products for plant care and soil and water management. Further information is available at: www.planthealthcare.com.





This information is provided by RNS
The company news service from the London Stock Exchange

You cant keep a good share down!

RNS Number : 0328E
Plant Health Care PLC
23 September 2008






23 September 2008










Plant Health Care plc

('Plant Health Care' or 'the Company')







IMPRESSIVE YIELD GAINS FROM PRETECT TRIALS




Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that independent trials of PreTect, the Harpin based foliar fertiliser, have resulted in impressive yield gains across a variety of crops.




The trials were undertaken in Spain, by SICOP a Spanish government approved trials agency, over the past 12 months as part of government required efficacy tests. The results of tests on olives, tomatoes, strawberries and lettuce showed significant improvements across a number of key metrics. These trial results were the final requirement for full registration of Harpin across all crops in Spain and will enable PHC to make shelf life and vigor claims in that market.




When a small amount of PreTect was applied to tomatoes, it led to an increase in flowering and fruiting maturity, and an increase of 2.6% in yield and over 20% in the key category of firmness. The increase in firmness is the parameter that dictates the shelf-life of tomatoes and therefore helps reduce wastage and increase farmers' profits. There were over 3.6 million tonnes of tomatoes produced in Spain in 2007.




Tests on olives showed an increase of 3.3% in yield and 5.4% in fruit size and most importantly a significant increase in oil content. There are currently around six million acres of olives harvested in Spain per year.




Results on lettuce indicated increases in yield of 4.3% per lettuce head and strawberries showed average increases of 5.8%.




John Brady, CEO of Plant Health Care commented, 'These results further validate the efficacy of PreTect following the announcement in June 2008 of its successful trials across a variety of soft fruits.




'A wealth of data has shown that PreTect offers an effective method of increasing the yield and shelf-life of a variety of crops. These results help to further position Plant Health Care as a key player in the worldwide effort to increase food production and quality while also reducing synthetic chemical use.'




- ends -




For Further Information:




John Brady
Evolution Securities Limited
Tavistock Communications

Chief Executive
Tim Worlledge/Tim Redfern
Jeremy Carey/Simon Compton

Tel: 001 603 525 3702
Tel: 020 7071 4300
Tel: 020 7920 3150

For release on RNS Reach:

25 September 2008










Plant Health Care plc

('Plant Health Care' or 'the Company')




FIRST MAJOR ORDER FOR NATURAL PRODUCTS SUPPLY AGREEMENT




Following the announcement of a multi-year supply agreement on 8 September 2008 with The Scotts Company ('Scotts'), Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces its first significant order for the supply of PHC's Natural Plant Food, for immediate delivery.




Scotts are the global leader in the consumer lawn and garden industry and under the terms of the agreement, Plant Health Care will supply Scotts with natural products for inclusion in their line of lawn and garden products for the retail market.




John Brady, CEO of Plant Health Care commented, 'This agreement allows us to participate in the retail markets with the global leader and is an important step towards our stated goal of becoming one of the world's leading developers and suppliers of natural products for plant health.









- ends

This lot only deal with good news!

RNS Number : 9078E
Plant Health Care PLC
02 October 2008




2 October 2008






Plant Health Care plc

('Plant Health Care' or 'the Company')




IMPRESSIVE YIELD GAINS FROM SOUTH AFRICAN HARPIN TRIALS




Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that independent trials of a Harpin based treatment, on commercial potato production in South Africa, have resulted in significant yield gains compared to conventional chemical treatments.




The comparison trials were undertaken in South Africa, by Bayagro, an important distributor to the potato industry, and presented to the Potato Seed Council of South Africa to show the efficacy of 20 combination chemical and natural potato treatments. This trial was conducted to establish a new 'best practice' for potato growing in South Africa.




The results showed that a Harpin based product, when used in conjunction with a standard treatment, yielded 8.1% more than all other treatments, including the current industry standard. These results have established Harpin as the new standard treatment for potato production in South Africa.




As a result of these successful trials Jason Holohan, Managing Director of UK/Spain, was invited as a guest speaker to address the recent annual South African Seed Potato Growers Forum. This forum represents growers from the potato industry in South Africa which harvests over 60,000 hectares.




John Brady, CEO of Plant Health Care commented, 'South Africa represents a new and exciting market for PHC. As a result of Jason's initiative in this market and the resultant successful trials we have received significant orders for the remainder of the 2008 season as well as for 2009. We now have a strong distributor in this market and look forward to initiating sales into a variety of crops with both Harpin and Myconate.'




- ends -

RNS Number : 1880K
Plant Health Care PLC
16 December 2008



16 December 2008







Plant Health Care plc

('Plant Health Care' or 'the Company')




PLANT HEALTH CARE AND MONSANTO SIGN FINAL AGREEMENT FOR THE COMMERCIALISATION OF HARPIN TECHNOLOGY







Plant Health Care Inc, a wholly owned subsidiary of Plant Health Care plc (AIM: PHC), and Monsanto Company (NYSE: MON) have entered into an agreement for the commercialisation of harpin-based technology as a seed treatment in Monsanto's major row crops and vegetables. The harpin technology offers farmers in-season benefits, including the suppression of pests like nematodes and yield-inhibiting diseases, as well as additive plant health benefits. The technology is a specific type of protein that activates a plant's intrinsic ability to protect itself and enhances growth. Over the past year Monsanto has evaluated the technology and will proceed to continue commercial development of harpin seed treatment as part of its global seed treatment platform.




Under the long-term agreement, Plant Health Care will license to Monsanto the exclusive rights to commercialise harpin seed treatment technology in corn, soybeans, cotton, canola and selected vegetables. In return, Plant Health Care will receive the milestone payment agreed under the Evaluation and Development Agreement announced in December 2007, plus ongoing royalties based on the total volume of Harpin seed treatment. As part of the agreement Monsanto will issue an order of product to be delivered by the end of this year. Financial terms were not disclosed, although Plant Health Care believes the agreement will make a material contribution to the company's future revenue and profits.




John Brady, CEO of Plant Health Care commented, 'This agreement, and the order for product which is 12 months earlier than anticipated, is transformational for Plant Health Care and is fundamental proof of our model for commercialising our technology portfolio in partnership with major industry players. Monsanto is an excellent partner, and its seed brands hold leading positions around the world.




He added: 'Plant Health Care's range of technologies, which includes harpin, are ideally placed to maximize yield benefits in today's environment of rising food prices and increased global demand for high-protein diets.'




Randy Barker, Monsanto's seed treatment strategy lead, said, 'We are pleased to be working with Plant Health Care to deliver technology that can provide plant health benefits. Seed treatments are a natural complement to our seed strategy and yield-enhancing technology, which enhance the profitability for our farmer customers.'




Monsanto seeds treated with Harpin may be available to farmers as part of its Acceleron brand seed treatment as early as 2010. Monsanto's Acceleron brand will represent a wide range of evolving seed-performance technologies dedicated to improving plant health.




For further information, please contact:




Plant Health Care plc
Monsanto Company

John Brady, Chief Executive Officer
Danielle Jany

Tel: +1-603-525-3702

Tel: +44-20-7920-3150 (16-19 December)
Tel: +1-314-694-2478

jabrady@planthealthcare.com
danielle.c.jany@monsanto.com




Evolution Securities



Tavistock Communications

Tim Worlledge / Tim Redfern
Jeremy Carey/Matt Ridsdale

Tel: +44-20-7071-4300
Tel: +44-20-7920-3150

tim.worlledge@evosecuties.com/

tim.redfern@evosecuties.com
jcarey@tavistock.co.uk / mridsdale@tavistock.co.uk

STOCKS NEWS Reuters Results diary

Europe Real-time Equity News

UK Stocks on the move

UK smallcaps



08:50GMT 16Dec2008-Plant Health Care rises on Monsanto deal

-----------------------------------------------------------

Shares in Plant Health Care rise 17.5 percent to 218 pence as the group reaches an agreement to license its harpin seed treatment to U.S. biotech company Monsanto Co for row crops and vegetables.

'Today's confirmation that Monsanto will deploy harpin in its seed-coating product for soybeans, corn, cotton and certain vegetables gives investors the long-term visibility they have been waiting for,' says Philip Sparks at Evolution Securities.

He estimates the deal could generate about 15 million pounds a year of earnings in the medium term, and the U.S. sales of harpin as a seed coating could be worth 450 pence per share on their own.

For more, click on

Reuters messaging rm://paul.sandle.reuters.com@reuters.net



08:47GMT 16Dec2008-Kesa falls on poor H1 results, downgrades

------------------------------------------------------------



Plant Health Care plc surges 16 percent after announcing its wholly owned subsidiary, Plant Health Care Inc, and Monsanto Co have entered into an agreement for the commercialisation of harpin-based technology as a seed treatment in Monsanto's major row crops and vegetables.

New article should please holders!

Click HERE

bid rumour

Seen/heard where, and who's in the frame?